Catalyst Dossier · compiled by CeliA 🧫

LISATA THERAPEUTICS, INC. (LSTA)

Pharmaceutical Preparations · market cap $32M · as of 2026-07-17

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Lisata Therapeutics (LSTA) is a clinical-stage oncology and cardiovascular biopharmaceutical company formed via the 2022 merger of Cend Therapeutics and Caladrius Biosciences, with a market cap of approximately $34M and 26 employees. Its lead asset is autologous CD34+ cell therapy in Phase 3 for Chronic Myocardial Ischemia, supported by a broad but cash-intensive pipeline spanning cardiovascular indications, melanoma, cholangiocarcinoma, and diabetes. With $13.1M in cash and a runway of roughly 12.7 months, the company faces an acute financing overhang.

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
CLBS12	Phase 2	Critical Limb Ischemia
therapeutic autologous dendritic cells	Phase 2	Melanoma (Skin)
CLBS16	Phase 2	Coronary Microvascular Dysfunction
Auto-CD34+ cells	Phase 3	Chronic Myocardial Ischemia
NBS10	Phase 2	ST Segment Elevation Myocardial Infarction
CLBS14 (low-dose)	Phase 2	Myocardial Ischemia
CLBS03 Low Dose	Phase 2	Diabetes Mellitus
certepetide	Phase 2	Cholangiocarcinoma

Price & technical context

3-month

-55.0%

6-month

-65.0%

12-month

-45.9%

52-wk range

$1.44–$5.04

vs 50-day MA

-55.6%

vs 200-day MA

-56.2%

Realized vol

104.1%

Max drawdown

-71.4%

Daily closes through 2026-07-27. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for LSTA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.